Analysts: Cree Is a Buying Opportunity and 3 More Research Notes to Look Over

Cree Inc. (NASDAQ:CREE): JPMorgan says that recent weakness in Cree following a mixed fourth-quarter report and guidance is a buying opportunity. The analyst believes that margin concerns are overblown and that the company has been somewhat supply constrained, giving it several levers to maintain margins. The shares are Overweight rated with a $75 price target.


Expedia (NASDAQ:EXPE): Benchmark Co. says that Expedia share weakness since the second-quarter report provides a good buying opportunity. The firm believes Expedia has been addressing the changing competitive landscape and that shares are undervalued. The shares were given a Buy rating and a $66 price target.


Williams-Sonoma (NYSE:WSM): After Williams-Sonoma reported stronger-than-expected results, Wells Fargo thinks the company’s guidance is conservative and keeps a Market Perform rating on the stock.


Amgen (NASDAQ:AMGN): UBS believes that Amgen’s acquisition of Onyx Pharmaceuticals (NASDAQ:ONXX) should improve Amgen’s 2015-2017 earnings per share growth trends, with its EPS growth reaching 14 percent by 2017. The firm previously predicted that Amgen’s EPS would grow only by low single-percentage digits from 2015-2017; it keeps a Buy rating on the stock.


Don’t Miss: Falling Jobless Claims Suggest Future Strength.